{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Background: \u2018Downstream\u2019 adverse outcomes associated with transfusion-related immune modulation (TRIM) occur postoperatively."
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "The main aim of this retrospective observational study was to evaluate the cost implications associated with perioperative adverse outcomes following allogeneic blood transfusion (ABT)."
      },
      "Participants": {
        "score": 2,
        "evidence": "Surgical patients (n = 2129) receiving blood transfusion at the Royal Brisbane and Women\u2019s Hospital (Queensland, Australia) (2016\u20132018) were included: receiving ICS only (n = 115), allogeneic red blood cells (RBCs) only (n = 1944), or RBCs and ICS (n = 70)."
      },
      "Intervention": {
        "score": 2,
        "evidence": "receiving ICS only (n = 115), allogeneic red blood cells (RBCs) only (n = 1944), or RBCs and ICS (n = 70)."
      },
      "Objective": {
        "score": 1,
        "evidence": "The main aim of this retrospective observational study was to evaluate the cost implications associated with perioperative adverse outcomes following allogeneic blood transfusion (ABT)."
      },
      "Method_Outcome": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Surgical patients (n = 2129) receiving blood transfusion at the Royal Brisbane and Women\u2019s Hospital (Queensland, Australia) (2016\u20132018) were included: receiving ICS only (n = 115), allogeneic red blood cells (RBCs) only (n = 1944), or RBCs and ICS (n = 70)."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "Most adverse outcomes (\u22653) occurred following RBCs and ICS (37.1%), followed by RBCs (23.7%) and ICS (16.5%)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Most adverse outcomes (\u22653) occurred following RBCs and ICS (37.1%), followed by RBCs (23.7%) and ICS (16.5%)."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 9,
    "max_score": 25
  },
  "model": "gpt-4o"
}